Dendreon to Present at Scientific and Financial Conferences Next Week - Poster Presentation at American Urological Association Annual Meeting SEATTLE, May 19 /PRNewswire-FirstCall/ -- Dendreon Corporation (NASDAQ: DNDN) today announced that the D9905 Phase 2 clinical trial results of Provenge(R) (APC8015), the Company's investigational immunotherapy for the treatment of prostate cancer, will be presented at the 2005 American Urological Association (AUA) Annual Meeting, taking place in San Antonio, TX, May 21-26. In addition, management will present at the Needham Biotechnology Conference next week. Details are as follows: Immunotherapy (APC8015) for Androgen Dependent, Biochemically-Relapsed Prostate Cancer. Poster presentation on Tuesday, May 24, 8:00 a.m. - 12:00 p.m. Central Time, Ballroom A, Presenter: Robert M. Hershberg, M.D. Dendreon Corporation. Fourth Annual Needham Biotechnology Conference Management will present at Needham's Fourth Annual Biotechnology Conference on Thursday, May 26 at 8:30 a.m. Eastern Time at the New York Palace Hotel. The presentation will be webcast live and available for replay from the "Investors/Webcasts & Presentations" section of Dendreon's website, http://www.dendreon.com/ and will be available for replay for 90 days. Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the development of innovative cancer treatments. In addition to its immunotherapies in clinical and preclinical development for a variety of cancers, Dendreon's product pipeline also includes monoclonal antibody and small molecule product candidates. Dendreon has research and development alliances with Genentech, Inc., Abgenix, Inc. and Dyax Corp. For more information about the company and its programs, visit http://www.dendreon.com/. NOTE: Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties that may cause actual results to differ materially from the results discussed in the forward-looking statements, particularly those risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov/. DATASOURCE: Dendreon Corporation CONTACT: Monique M. Greer, Sr. Director, Corporate Communications of Dendreon Corporation, +1-206-829-1500 Web site: http://www.dendreon.com/

Copyright